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Abstract
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or
phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in
personalized medicine. However, its promise has not always translated into improvements in patient care due to
the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be
costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs.
There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple
findings including general considerations; influence of pharmacogenomics on response and toxicity of drug
therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new
targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized
medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed
to enhance its uptake and funding to benefit patients.
Keywords: Biomarkers, Drug development, Genomics, Genotyping, Healthcare policy, Pharmacogenetics precision
medicine, Personalized medicine, Health authorities, Rational use of medicines, Reimbursement, Targeted
treatments
Introduction
General
Considerable variability exists in how individual patients
respond to pharmacological treatments. Differences in
patients’ individual make-up arising from genetic, bio-
logical, behavioral and environmental factors are seen
as causes of this variability [1-15]. Patients’ genomes
account for an estimated 20% to 95% of the variation in
drug disposition [16,17]. This variability translates into
differences in clinical outcomes including therapeutic
benefit and side-effects [14,15,18-22]. As a result, differ-
ent dosing regimens may be needed. However, current
treatment regimens still tend to use ‘general or average’
doses [3-5,9,13,14,22-25], calling for a more tailored ap-
proach in the future [14,26].
Some physician groups already specify different treat-
ments and doses taking into account factors such as
patients’ ages, gender, family history and current co-
morbidities [5,27], and this is expected to continue. For
instance, tamoxifen for many years has been standard
treatment for patients with breast cancer with estrogen
receptor sensitivity [26,28-31], but not when these
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receptors are absent. Omalizumab, a recombinant human-
ized antibody to IgE, is only recommended for patients
with asthma uncontrolled with chronic steroids and who
have convincing IgE-mediated asthma [32], with serum
IgE levels used to determine subsequent doses. However,
there continues to be controversy surrounding its effect-
iveness in clinical practice and its cost-effectiveness [33].
The recognition of the complexity of the various bio-
logical systems involved in different diseases [14,34]
helps explain why there are a high number of non-
responders to certain drugs (as high as 30% to 70%, or
more) [1,5,35-37]. This in turn translates into an
increase in the number of patients needed to treat, lead-
ing to physicians adopting trial-error paradigms when
treating patients [27]. Inter-individual variability in pa-
tients’ responses can also increase adverse events and re-
duce effectiveness, or both [1,4,5,17,18,22,26,38-43],
leading to sub-optimal care and adding to the costs of
care. Increasing knowledge of the complexity of bio-
logical systems is also challenging drug development
policies. This helps to explain why, between 2007 and
2010, for instance, 90% of drugs failing during phase II
tests or in submission to the US Food and Drug Admin-
istration (FDA), failed due to either a lack of efficacy
(66%) or a link to safety concerns (21%) [16,22,44-48].
As the knowledge of biological systems grows, drug
pipelines should become more productive as well as im-
prove subsequent patient care [8,9,13,35,36,49,50]. Be-
tween 1976 and 2005, 28 drugs were withdrawn from
the market in the US due to idiosyncratic serious side-
effects including hepatotoxicity, nephrotoxicity and
rhabdomyolysis [18,51,52]. Specific examples include
cerivastatin and mibefradil, both of which had favorable
benefit-risk profiles at market authorization, but their
use in clinical practice, coupled with physicians ignoring
recommended guidance, caused their withdrawal [1,53].
Perhexiline was highly effective in treating angina;
however it was associated with severe and unacceptable
hepatotoxicity, leading to its withdrawal. This did not hap-
pen in Australia and New Zealand, where usage was linked
to pre-treatment phenotyping and therapeutic drug moni-
toring. This is because side-effects, including neuropathy,
had been linked to patients being poor or intermediate
metabolizers of CYP2D6 [5]. As a result, instigating routine
pharmacogenetic testing at its launch may have prevented
its withdrawal [5,54-57]. Dosing of thiopurines such as aza-
thioprine according to patients’ thiopurine methyl transfer-
ase status can reduce subsequent drug-induced morbidity
among patients with rheumatologic and inflammatory
bowel disorders [19-21,58], potentially reducing discon-
tinuation [20,21,58]. In addition, measuring thiopurine me-
thyl transferase levels to substantially dose thiopurines can
reduce the time taken to adequate dosing, helping with
subsequent remission [59].
A different example is natalizumab, which was ap-
proved in 2004. In patients with relapsing remitting mul-
tiple sclerosis, natalizumab significantly reduced the
number of relapses and the development of new in-
flammatory lesions [60,61]. However, natalizumab was
withdrawn soon after its launch due to the development
of progressive multifocal leukoencephalopathy (PML)
resulting from reactivation of JC virus [60,61]. This was
a major concern as PML is a devastating condition, leav-
ing survivors with serious impairment. Natalizumab be-
came available again in Europe in 2006 under strict
prescribing regulations [60,61]. Programs are ongoing to
investigate whether seropositivity for JC virus antibodies
will help accurately predict the development of PML
[60] as well as improve understanding of the risks of pa-
tients developing PML if they remain seronegative to JC
virus and, alternatively, the risks of developing PML if
they convert from seronegativity to seropositivity. As a
result, these tests have the potential to improve the
benefit:risk ratio. This continual re-evaluation is impor-
tant to avoid unpredictable events.
These examples illustrate the opportunities and chal-
lenges that are concomitant with greater knowledge
about disease progression and treatments.
Resource issues
Adverse drug reactions (ADRs) add to the costs of
healthcare by increasing hospital admissions [62-70].
Average treatment costs for a single ADR in Germany
have been estimated at approximately €2,250, equating
to €434 million per year [63]. The cost of emergency-
related admissions in the UK because of ADRs has been
estimated at GBP£2 billion annually [64]. It is estimated
that more than 2 million people are hospitalized an-
nually in the US through serious adverse events [22,71],
and hospital admissions related to warfarin complica-
tions costing on average US$10,819 per patient [72].
Overall, the cost of drug-related morbidity and mortality
exceeded US$177 billion in the US in 2000 [35].
Hospital admissions accounting for nearly 70% of the
total costs followed by long-term care admissions (18%)
[22,73]. ADRs are also a challenge to healthcare institu-
tions in low income countries [68].
Improved knowledge of pharmacogenomics could
potentially reduce ADRs [15,18] through, for instance,
improved identification of host genetic factors predis-
posing patients to increased toxicity to certain drugs
[15,16,18,22,38,39,74,75].
In Europe, the current financial crisis makes resource
issues especially important. Pharmaceutical expenditure
has been growing at a faster rate than other components
of ambulatory care [76-83], equating to 50% in real terms
among Organisation for Economic Co-operation and
Development countries between 2000 and 2009 [83,84].
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As a result, pharmaceutical expenditure has become the
largest or equaling the largest cost component in ambula-
tory care in many countries [78-83,85]. New premium-
priced drugs, especially new biological drugs at US
$100,000 to US$300,000 per patient per year or more, are
adding to these pressures, challenging the ability of society
to continue to provide equitable and comprehensive
healthcare [82,83,86-88]. Some countries are already not
reimbursing new premium-priced drugs [89,90], which is
not in the best interest of any key stakeholder group.
Consequently, it is attractive to tailor treatments and
resources to patients according to their genetic, medical
and behavioral factors to achieve the greatest health
gain, minimizing waste and maximizing the number of
patients needed to harm [4,5,8,9,14,16,18,22,23,36,45,
74,91,92]. This should result in healthcare systems
maximizing the improvement in the health of their pa-
tients with available resources. It may also lead to the
stratification of treatments according to their health gain
becoming a major factor in future reimbursement con-
siderations for new premium-priced drugs.
We are already seeing capacity building in genomics
medicine and molecular diagnostics growing across
countries, including Sri Lanka and Asia-Pacific countries
[93-95]. This is likely to continue with new develop-
ments and resources.
Objectives and definitions
Personalized medicine and personalized healthcare are
not new concepts [27,44,47,96,97]. Personalized medi-
cine was initially established in oncology, where new
therapeutic concepts could be developed upon the pre-
cise description of disease-specific mutations. As a re-
sult, new strategies evolved such as targeted therapies
and signal interception-based therapies. However, for the
purposes of this paper, personalized medicine not only
refers to the choice of therapeutic strategies in terms
of direct target selection but also involves a degree
of pharmacogenomics and genetic testing to improve
patient care [16], agreeing with other authors [26,98,99].
We recognize that the development of personalized
approaches is complex. This is illustrated by recent re-
search in breast cancer, suggesting that this cancer con-
sists of many different types of tumors [100]. Greater
knowledge of this diversity should lead to developments
that improve the sensitivity and specificity of prognostic
and diagnostic biomarkers; this should also lead to more
effective treatments [11,100-102]. We believe greater
targeting of treatments has the potential to revolutionize
healthcare delivery through improved effectiveness of treat-
ments and reduced side-effects and associated costs, as
well as reducing the number of product withdrawals
[18,26,27]. Current knowledge is already resulting in the
growth of medicines that require genetic testing before
administration [4,5,11,13,15,19,21,45,46,49,86,91,103-106].
This will continue given the number of targeted treatments
as well as genomic tests in development [45,107]. We also
expect to see more accreditation of laboratories performing
genomic testing of specific molecular genetic traits to im-
prove the interpretation of laboratory results [16]. This ac-
creditation will address concerns where there has been
variation in test results depending on the detection meth-
odologies used [13,108]. The sensitivity and specificity of
pharmacogenetic tests is important as this will affect their
cost-effectiveness and subsequent utilization [98,99].
However, as in many growing fields, the promises
associated with pharmacogenomics have not always
translated into appreciable improvements in patient care
[14,22,47]. This includes the clinical utility of genomic
tests for which a national expert panel (Evaluation of
Genomic Applications in Practice and Prevention; EG
APP) in the US only recommended one of the four tests
initially evaluated for routine use, with the need for
more evidence in two [107,109,110]. It is recognized that
there are a number of barriers that need to be addressed
before pharmacogenomics will be part of routine clinical
care [27]. These include a redirection of drug develop-
ment towards tailored therapies [23,36,92], which is
already happening [45,86,111]. Major issues regarding
the funding of genetic and biomarker testing, especially
high cost tests, also need to be addressed given the
current and diverse funding structures between ambula-
tory and hospital care, and the fact that traditional diag-
nostic tests have typically been low priced [35,45,74,75].
Instigation of projects such as EGAPP will help improve
the systematic way in which tests are evaluated for their
potential clinical utility to help with funding decisions.
Other barriers include addressing health authority and
health insurance (‘payer’) concerns that companies will
seek high prices for new targeted treatments through
seeking orphan status [82,86-88,112-116]. There may also
need to be changes during drug development processes,
including clinical trials, where sub-populations will con-
tinue to shrink to fulfill licensing and reimbursement re-
quirements. This includes better identification of patients
likely to have an improved benefit:risk profile because of
their pharmacogenetic profile.
Consequently, the objective of this review paper is to
integrate current knowledge about the value of bio-
markers and prognostic tests to improve patient care, as
well as potential concerns, from a payer’s perspective.
This is because published articles have generally not
been written with this in mind. As a result, we hope this
paper will provide guidance to all key stakeholder groups
on potential ways to enhance future utilization and
funding of new personalized approaches. This will be
achieved by reviewing the current situation regarding per-
sonalized medicine, principally based on peer-reviewed
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papers, building on comments in the background; apprais-
ing key funding, organizational and healthcare issues that
need to be addressed; and suggesting potential ways for-
ward for all key stakeholder groups to enhance funding
and utilization of new diagnostic and prognostic tests as
well as new targeted drug treatments through an iterative
process involving the co-authors.
We will consider the need to distinguish between gen-
etic tests that demonstrate a particular patient has sus-
ceptibility to a given disease and developments that help
determine a patient’s responsiveness to a given drug
and/or the potential for adverse reactions [5,10,117].
We are aware of the considerable controversies sur-
rounding unregulated direct-to-consumer (DTC) genetic
testing [118] and we will briefly mention this.
Review
The findings are consolidated under various headings, in-
cluding general considerations, pharmacogenomics, bio-
markers, challenges and concerns, and key issues for
healthcare funding bodies to address.
General considerations
Multiple definitions have been assigned to personalized
medicine, including stratified medicine. Essentially all
definitions include targeting of diagnostic or treatment
approaches to improve the future care of patients
[2,8,16,23,26,27,45,50,98,119,120].
As we explore the molecular pathophysiology of differ-
ent diseases, we find increasing examples of genetic dif-
ferences as explanations for inter-individual variability in
drug responses [1-5,8-11,16,22,37,47]. For example, the ef-
ficacy and safety of codeine is influenced by CYP2D6 poly-
morphisms, explaining why slow CYP2D6 metabolizers
lack an analgesic effect with codeine and why ultra-rapid
metabolizers may experience adverse effects on thera-
peutic doses [16,22,38,39]. Greater knowledge allows the
possibility to redefine patient subgroups for drugs to en-
hance their effectiveness and/or reduce their toxicity.
Consequently, improved knowledge of biomarkers will en-
rich the management of diseases from prevention to treat-
ment depending on the availability of targeted therapies.
Greater knowledge should also enhance the use of existing
therapies, reducing reliance on new premium-priced ther-
apies. Whether this happens remains to be seen, especially
given that, despite many decades of scientific advances,
only a few genotyping or phenotyping tests are currently
being used routinely in clinical practice [4,5,10,11,13,16,
21,36,105,121,122]. This is because of increasing know-
ledge and awareness that a given patient’s genomic and
phenotypic make-up is appreciably more complex than
initially believed, as well as the influence of environmental
factors [1,9-12,16,36,49,117,122]. As a result, different
approaches are required to separate diseases into
different subgroups. These include new technology
platforms and mathematical models of different ap-
proaches and consequences, including system biology
approaches that replicate diseases, to truly realize ‘person-
alized medicine’ [8,34,36,44,123]. This will be helped by
the continued development of patient-centric, longitudinal
and cross-institutional electronic health records containing
genetic information and genomic test results, while ensur-
ing patients’ privacy through appropriate data encryption
and privacy protection [44,124].
Pharmacogenomics and response and toxicity to drugs
Pharmacogenomics includes the identification of host
genetic factors that influence drug absorption, metabol-
ism and action at the receptor level, which could subse-
quently reduce patient numbers needed to treat and
minimize toxicity [125,126]. There are a number of ex-
amples of pharmacogenomics being applied across dis-
eases areas. These can be summarized into tests that are
associated with increased response rates and those that
predict toxicities to improve future care (Table 1).
For example, independent genome-wide studies in-
volving patients with chronic hepatitis C infection, who
were treated with pegylated interferon alpha and ribavi-
rin, showed an association between a variant in the host
genotype of IL28B and drug response [127-129]. In view
of this, genotyping for IL28B is increasingly undertaken
in hepatitis C clinics [4]. Poly(adenosine diphosphate–
ribose) polymerase (PARP) inhibitors are also showing
promise in a subgroup of patients with triple negative
breast cancer who have inherent defects in DNA repair.
This makes this particular breast cancer a rational target
for therapy based on PARP inhibition [138]. Models have
also been developed, including four polymorphisms in
the AMPD1, ATIC, ITPA and MTHFD1 genes, to help
predict response to methotrexate, leading to greater tai-
loring of treatment [139].
Pharmacogenomics has also been effective in helping
to predict toxicities to treatment. Examples include
(Table 1) testing prior to initiating abacavir in patients
with HIV type 1. It is estimated that between 48% and
61% of patients with the human leukocyte antigen-B*5701
allele will develop a hypersensitivity reaction to abacavir,
which can be life threatening if repeated, compared with
to 0% to 4% of patients who do not have this allele
[1,4,35,140]. This resulted in the FDA modifying the
abacavir label to include a recommendation that patients
should undergo allele testing before initiation [125]. There
is also awareness that dihydropyrimidine dehydrogenase
deficiency may need to be tested for in patients prior to
initiation of 5-fluorouracil (infusion or oral tablets) for
the management of their gastrointestinal cancer. Full
dihydropyrimidine dehydrogenase deficiency can be fatal
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but rare in practice; however, partial deficiency is present
in 3% to 5% of patients [136].
Biomarkers to target treatment approaches
The National Cancer Institute in the US defines a bio-
marker as a biological molecule found in blood, other body
fluids, or tissues that is a sign of a normal or abnormal
process, or of a condition or disease [117,141]. Biomarkers
are increasingly being used in the field of cancer as well as
other disease areas (Table 2). They are also being investi-
gated in the field of psychiatry including directing treat-
ment approaches in patients with schizophrenia [142].
The importance of incorporating biomarkers into drug
development is illustrated by gefitinib. Gefitinib was
given conditional approval in 2003 for the treatment of
chemorefractory metastatic non-small cell lung cancer.
However, a large trial assessing the efficacy of gefitinib
in an unselected patient population failed to show a sur-
vival benefit [158]. This led the FDA to re-label gefitinib
restricting its use to patients that were already using the
drug and benefiting from it. Subsequently, it became ap-
parent that patients with tumors that have Epidermal
Growth Factor Recepetor (EGFR) -activating mutations,
which are present in 10% to 26% of non-small cell lung
cancers, significantly benefited from gefitinib compared to
standard chemotherapy [1,23,159-162]. As a result, the
FDA altered the label of gefitinib to include its use in pa-
tients with tumors that are EGFR-activating mutation
positive. These patients will also have increased
responsiveness to the tyrosine kinase inhibitors erlotinib
and afatinib (Table 2) [163-165]. Not surprisingly, with
new ways to identify subgroups of tumors with response
to specific drugs, it is becoming a prerequisite in oncology
for companies to design clinical trials with genetic bio-
markers [36,49,91,125,171,172].
Examples of targeted treatments in non-cancer areas
include maraviroc for patients with HIV (Table 2).
Maraviroc is only effective against CCR5-tropic HIV,
and patients with viruses that use both the CXCR4 and
CCR5 receptors for entry into the cell (dual/mixed tropic)
Table 2 Examples of tumor-specific biomarkers to determine eligibility for targeted therapy
Disease Biomarker Drug References
Colorectal cancer KRAS Cetuximab, panitumumab [1,2,11,13,27,86,98,108,125,143,144]
Breast cancer Estrogen receptor Tamoxifen [28-31]
Breast cancer Human Epidermal Growth Factor Receptor 2
(HER 2)
Trastuzumab, pertuzumab, lapatinib,
trastuzumab emtansine (TDM1)
[1,2,11,27,125,145-154]
Melanoma BRAF Vemurafenib, dabrafenib [34,112,155-157]
Non-small cell lung
cancer
Epidermal Growth Factor Receptor (EGFR) Gefitinib, erlotinib, afatinib [1,23,158-165]
Non-small cell lung
cancer
Anaplastic Lymphoma Kinase (ALK) inhibitors Crizotinib [91,163,166,167]
Chronic myeloid
leukemia
Philadelphia chromosome levels Imatinib, nilotinib, dasatinib [168,169]
CCR5-tropic HIV CXCR4, CCR5 receptors Maraviroc [170]
Cystic fibrosis G551D mutation Ivacaftor [88]
Table 1 Examples of pharmacogenomics tests regarding responses or toxicities to drug treatments
Disease area Host genotype Treatment References
Optimizing drug efficacy
Chronic hepatitis C IL28B Pegylated interferon alpha, Ribavirin [127-129]
Breast cancer, other tumors Anthracyclines, poly(adenosine diphosphate-ribose)
polymerase inhibition
[117,130-132]
Preventing drug toxicities
HIV type 1 (HLA)-B*5701 Abacavir [1,4,35,106,133]
Rheumatic and inflammatory
bowel disorders
Thiopurine methyl transferase
genotypes
Azathioprine [19-21,58,59,133-135]
HLA-B*58:01 Allopurinol
Gastrointestinal cancers Dehydropyrimidine
dehydrogenase deficiency
5-fluorouracil [136]
UGT1A1 polymorphism Irinotecan [137]
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will not respond [170]. Consequently, it should not be ini-
tiated in these patients. Awareness of the fact that the
funding and prescribing of maraviroc may be challenged
by the cost of testing, at up to US$1,960 per patient,
resulted in the company covering these costs themselves
[35]. However, the cost of this test was fully covered by in-
surance companies in the US within twelve months of its
launch [35].
There has also been a search to identify easy-to-use
biomarkers. Recently, a simple blood test to detect cir-
culating tumor cells in patients with breast cancer has
been reported to offer prognostic information [132].
Blood tests are also being developed to rapidly predict
which patients will respond to anthracyclines or PARP
inhibition [117,130-132]. Patient management is clearly
being improved with the use of biomarkers with
existing drugs. This, along with increasing knowledge
of gene expression and aberrant signaling pathways
[13,49,117,142,173-175], should increase the number of
drugs that can be more rationally prescribed and dosed
using biomarkers, and also broaden the use of
established drugs.
Challenges and concerns for routine use of diagnostic tests
There have been controversies and concerns regarding
the routine use and funding of some pharmacogenetic
tests. This is in view of their sensitivity, specificity, asso-
ciated costs or a combination of these factors.
The EGAPP group [110] had concerns with three out
of the first four tests evaluated [107,109]. These included
tumor gene expression profiles to improve outcomes in
defined populations of women with breast cancer,
CYP450 testing of drug metabolic capacity before
treating adults with depression with selective serotonin
re-uptake inhibitors and population screening for heredi-
tary hemochromatosis [107,109,176]. There are ongoing
debates regarding the utility of CYP2D6 genotyping testing
prior to initiating tamoxifen [5,28-31,177]. In November
2010, this resulted in the UK Medicines and Healthcare
Products Regulatory Agency no longer recommending
genetic testing prior to treatment with tamoxifen [5,178].
There are also continuing controversies surrounding
genetic testing prior to initiation with either clopidogrel
or warfarin. Studies suggest there is an increased risk of
adverse cardiovascular outcomes if effective and safe
drug concentrations of these drugs are not reached
[4,5,125,179]. This includes in patients with allelic variants
of the genes CYP2C19 and VKORC1. This resulted in the
FDA revising the label for clopidogrel in June 2009 to
include a section on pharmacogenetics explaining that
several CYP enzymes convert clopidogrel to its active
metabolite and that the patient’s genotype for one of these
enzymes (CYP2C19) could affect its activity [5]. More re-
cently, a number of studies have reached different
conclusions making the situation unclear [125,179-184].
As a result, the American College of Cardiologists in 2010
advised that the predictive value of pharmacogenetic test-
ing prior to clopidogrel therapy is limited and the evi-
dence base is insufficient to recommend routine testing
[185]. This has been endorsed by two recent meta ana-
lyses, both of which failed to show a substantial or
consistent influence of CYP2C19 polymorphisms on
subsequent cardiovascular events [184,186]. The Me-
dicare Evidence Development & Coverage Advisory
Committee, Centers for Medicare and Medicaid Ser-
vices, had concerns with genotype-guided dosing of
warfarin [109]. They suggested a genotype-guided test
could still be used but should be accompanied by evi-
dence development in view of the uncertainties in-
volved [41,109,187]. As a result, they did not endorse
routine pharmacogenetic testing prior to initiating war-
farin. This may change with recent data suggesting that
up to 50% of the variation in the dose of warfarin
needed may be explained by genetic factors [188]. Re-
cent studies also suggest that genetic information on
CYP2C9 and VKORC1 is important both for the initial
dose finding stage with warfarin as well as during main-
tenance therapy [188].
There is also continuing debate about the funding of
BRCA testing and Oncotype DX in terms of their associ-
ated costs and cost-effectiveness in practice. This is illus-
trated by variable funding among private and public
insurance plans in the US for BRCA testing for patients
at high risk of developing breast cancer, exacerbated by
charges of US$3,340 per patient for full sequence testing
[121,189]. Nevertheless, the National Institute for Health
and Care Excellence (UK) currently recommends that
BRCA1/2 testing should be offered to patients if the like-
lihood of detecting a mutation is greater than 20%, al-
though many testing centers offer the test if the
likelihood is between 10% and 20% [190,191]. Wider
usage is currently difficult to endorse in view of the costs
involved [191]. This may change with recent research
showing that women in the UK diagnosed with triple-
negative breast cancer under 50 should routinely be of-
fered BRCA1/2 testing to optimize subsequent treatment
options that the genetic information makes possible
[190,192]. However, such a move would result in an
extra 1,200 tests a year in the UK [191]; although some
of costs could be offset by reduced waste.
The Oncotype DX breast cancer assay is a 21-gene assay
conducted on a patient’s tumor specimen to estimate the
risk of recurrence post surgery specifically in patients with
hormone-positive, lymph node-negative breast cancer. It
can also provide further information on the benefits pa-
tients will derive from postoperative chemotherapy. The
impact of the Oncotype DX score was evaluated prospect-
ively and led to treatment changes in 30% of cases [193].
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Both the American Society of Clinical Oncology and the
US National Comprehensive Cancer Network guidelines
endorse its use in early stage hormone-positive breast can-
cer [121,194]. Despite these recommendations, and two
Canadian studies showing that molecular classification
with this test is clinically useful and cost-effective
[195,196], funding for this assay remains variable among
the Canadian provinces. This can be largely attributed to
the average cost of a test at CA$4,000 [194]. In 2010,
British Columbia began a registration study for the 21-
gene assay. However, it was restricted to node-negative
cases and, until recently, was active only in the main Van-
couver clinic. In 2010, Ontario started funding the 21-gene
assay more consistently, with prior authorization needed
for out-of-country cases. Recently, Quebec’s public system
has also started funding an increasing number of these tests
[194].
There is also an Oncotype DX colon cancer assay,
which is a 12-gene assay to predict recurrence after re-
section of stage II and III colon cancer. This assay has
been validated in a number of studies [197-199]. When
conducted on tumor specimens of appropriately selected
patients with stage II colon cancer, there was a 17% re-
duction in the use of postoperative chemotherapy and,
similar to breast cancer, the Oncotype Dx colon cancer
assay led to a change in a patient’s treatment in a third
of cases [200]. The test is currently not funded by any of
the Canadian provinces, but has been funded through
Centers for Medicare and Medicaid Services in the US
since September 2011.
The costs of pharmacogenomics testing are envisaged
to fall appreciably with their increasing use [44,201].
This should enhance their funding and use provided
there is robust evidence including details of their sensi-
tivity and specificity. Reimbursement will also be en-
hanced if the current heterogeneity in funding systems
can be resolved where pertinent [27].
Future research priorities including strategies between
the US Food and Drugs Administration and the European
Medicines Agency
These case histories illustrate why it is crucial for re-
searchers and commercial organizations to obtain data
from trials demonstrating any association between bio-
markers and disease outcomes to enhance future en-
dorsement and funding of diagnostic tests. The same
holds for new targeted treatments. Alongside this, a co-
hesive vision of what personalized medicine will consti-
tute must be developed. The instigation of groups such
as the Personalized Medicine Consortium and European
Medical Research Council and the combining of research
group activities should help with this [1,16,46,47]. European
initiatives such as Information and Telecommunication for
the Future of Medicine [202] should also help with study
design through developing methodologies incorporating
multiple forms of evidence such as those from different
genetic databases [27]. This includes the findings from the
1000 Genomics Project Consortium [203]. Implementation
of guidance at the public health level such as the Public
Health Genomics European Network II guidelines for the
provision, quality assurance and use of pharmacogenomic
tests [27] should help enhance the adoption of new tests in
a rational manner.
Pharmacogenomic research should be strengthened by
bodies such as the International HapMap Consortium,
the 1000 Genomes project [16], the Mutanom project
(German National Genome Research Network - NFGN -
combined with Integrated Genomic Research Network -
IG) [44], Pharmacogenomics Research Network [46] and
the International Cancer Genome Consortium [47].
It is recognized that full targeting of diagnostic and
treatment approaches will require appreciable under-
standing of the genetic background for different diseases
and patient populations, rather than just the expression
patterns of single gene associations. This has been dem-
onstrated by the variable predictive yield of genome-
wide association studies to date [14,18,46,47,171]. As
mentioned, this can be explained by the complex nature
of biological systems, which have shown to operate in
far more complex ways than originally thought.
Future developments may include improved translation
of single and combined biomarker test information. They
may also include developments in technology platforms,
mathematical models and systems biology [2,17,36,46],
thereby reducing the heterogeneity of currently treated
populations through smaller subgroups [13,37,77]. How-
ever, this will require more extensive basic and clinical re-
search than is currently being funded [9,204].
It is also recognized that clinical trials to evaluate new
tests and/or targeted treatments may be complex and
costly, and may also pose serious organizational and eth-
ical problems if there are multiple subgroups with differ-
ent treatment strategies [98,99]. This calls for new study
designs, potentially including sequential testing. One
way forward could be to have clinical trial and observa-
tional study evidence combined with systems biology
modeling such that multiple trials validate the mathem-
atical models produced. These can subsequently be
used to predict treatment effect for individual patients
and their tumors [34,44]. However, such studies need spe-
cific objectives including the prospective definition of
diagnostic, screening or prognostic biomarkers alone and/
or in combination before any studies are undertaken
[28,98,99,117,162,205]. Innovative funding strategies may
also be needed to accelerate the introduction of new val-
ued targeted treatment approaches until their costs come
down [44,201]. The combination of prospective clinical
trials and observational studies may also accelerate the
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translation of clinical research results into routine medical
practice [2].
It will be increasingly important for the European
Medicines Agency and the FDA to collaborate on the
development and establishment of harmonized guide-
lines for genotyping and biomarker testing, and their in-
corporation into future targeted treatments, to guide
companies [133]. This could include standardizing trial
data documentation. The importance of this is empha-
sized by up to 50% of current clinical pipelines among
leading companies include targeted or stratified medi-
cines [45]. In addition, as mentioned, in oncology it is
becoming a prerequisite for pharmaceutical companies
to design clinical trials wich include biomarkers.
Key issues for healthcare and funding bodies
General
As this field evolves, the clinical utility in shaping pa-
tients’ treatment should become realistic [2]. However,
several issues need to be addressed.
Key issues include clearer co-ordination between the
various bodies responsible for funding of care and those
evaluating new treatment approaches [13]. Improved co-
ordination should help to assimilate more rapidly proven
developments of value into routine clinical practice. This is
happening, for example in France, with the simultaneous
assessments of new diagnostic technologies by the Com-
mission Nationale d’Evaluation des Dispositifs Médicaux et
des Technologies de Santé, and the evaluation of new
drugs and their associated diagnostic test by this institution
together with the Transparency Commission [35].
There also needs to be effective strategies that address
current concerns among health authority and health in-
surance personnel regarding personalized medicine. This
is because there are currently few examples of
pharmacogenetic tests being integrated into routine care
despite the initial optimism. In addition, the advice on
whether to fund specific tests has changed on a number
of occasions as more research data becomes available.
Accommodating these costs will not be easy, especially
with growing resource pressures [1,35]. However, there
is willingness among payers to consider new tests and
treatments given the resources that are currently being
wasted as clinicians try different treatment approaches
as well as the costs of treating ADRs [27,62-73]. The
costs for any pharmacogenomic tests associated with
new targeted treatments need to be made explicit in any
health technology assessment of new drugs, including
the potential budget impact.
As a result, there are a number of medical, ethical,
legal, social, economic and organizational issues that
need to be considered as the field of personalized medi-
cine grows (modified from [27,109]):
Medical issues
 Improvements in clinical effectiveness through
tailoring treatments including their impact on length
and quality of life as well as number of patients
needed to treat
 Improvements in drug safety profiles/reductions in
adverse drug reactions increasing the number of
patients needed to harm rates
 Relevance of surrogate results (diagnostic
technologies)
 Opportunities for preventive measures and
interventions
 Proportion of patents affected/re-classified
 Need for post-marketing follow-up (post-
introduction assessment) and not just
pharmacovigilance
 Improved knowledge of pharmacogenomics among
physicians
Legal issues
 Reassessing existing drugs and other technologies
 Redefining existing regulatory policies
 Need for including biomarkers that support
indications and clinical decision making
 Maintenance of citizens’ autonomy
 Legal liability associated with targeted tests
 Protection of any patient information generated
 Whether professional ethical guidelines become
statutes or mandatory guidelines
 Harmonization of laws in different contexts
 Patients’ autonomy
 Advertising - particularly direct-to-consumer
advertising
 Harmonization of free movement of services to
avoid or reduce citizens’ misconceptions and
potentially unlawful practices
Economic issues
 Reduction in costs to healthcare systems with
greater personalized approaches
 Who pays for diagnosis - healthcare systems,
manufacturers or patients? This especially with
current fragmentation of care and budgets
 Budget impact of new technologies and other
considerations for reimbursement and funding
including cost and Quality Adjusted Life Year
considerations
 Whether the inclusion of biomarkers will lead to
more clearly defined subpopulations and indications
for reimbursement (in addition to regulatory
considerations)
 Potential changes in reimbursement considerations
and policies with smaller populations and targeted
treatments
 Redefining the conditions for orphan status for new
targeted treatments
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 Financial incentives for citizens; active role of the
citizen in his/her own health and wealth
 Co-development of drugs and genome-based
diagnostics that more tightly define indications or
subpopulations - requirements for approval and/or
incentives for reimbursement at premium prices
Ethical issues
 Change in the concept of health and disease
(prediction)
 Ownership of the information (not only genomic)
 Sufficient understanding to justify population-based
genome sequencing
 Accessibility of diagnostic tests and targeted treatments
within and across countries with companies seeking
‘orphan status’ for new targeted treatments
 Patients’ understanding and patients’ role in future
decision making
 Human dignity - potential for stigmatization and
discrimination
 Human integrity - how this affects moral
convictions, preferences and commitments
Social issues
 Empowerment and increasing autonomy of patients
and their relatives
 Stigmatization of certain subpopulations according
to their genomic, clinical and environmental data
 Current technology makes internationalization of
data possible
 Policies to promote the implementation of
personalized health services:
○ people and subgroups involved
○ support required
○ costs involved
○ people’s reaction for or against such services
(qualitative and quantitative research)
 Legal barriers concerning different reimbursement
and pricing policies that have an impact on the
implementation of personalized healthcare services
and products. This can cause inequity or unequal
access to new technologies if not addressed
Organizational issues
 Emphasis on wellness and disease prevention
 Change in health services paradigm with primary
care and public health playing a greater role with
greater stratification of patients resulting in potential
changes in work- and patient-flow processes
 Greater patient empowerment and shared decision-
making:
○ Scheduled time dedicated to patients
○ Healthcare professional training on genomics
including health literacy among providers
○ Management of genomic information and its
consequences
○ Acquisition of shared decision-making skills
 Potential centralization of diagnostic
services
 Potential decentralization of decision-making
processes
 Monitoring of physician adherence to any tightly
defined subpopulations; potential ways to enhance
adherence where concerns
 Funds made available for data protection and
complex computing systems
Overall, the medical, ethical, legal, social and eco-
nomic challenges for personalized medicine are not
unlike the scientific uncertainty, assessment, cost-
effectiveness and access issues affecting traditional
medicines. However, diverse ethical and social princi-
ples and their interpretation often lead to disparate
views on the safety, equity and desirability of personal-
ized therapy. For example, publicly directed genetic
testing including newborn screening is being chal-
lenged to demonstrate, on the one hand, that informed
consent, confidentiality and information accuracy are
adequate and, on the other hand, that public and pri-
vate good do result from identifying genetic abnormal-
ities [206].
In addition, there must be discussion whether identifi-
cation of a genetic predisposition, regardless of manifest-
ation, could lead to denial of healthcare, insurance,
employment or educational opportunities [207]. In terms
of psychiatric conditions, there must also be a debate on
how Health Technology Assessment (HTA) can balance
the harm of stigmatization and discrimination based on
a genetic sequence potentially related to a mental illness
with the availability, affordability and effectiveness of
prevention or treatment [208].
A key ethical concern going forward is equitable ac-
cess to personalized therapies, which may affect drug de-
velopment decisions. There may be, for example, fewer
incentives for companies to develop drugs for ‘less prof-
itable’ genotype groups [209]. If such practices increas-
ingly become the norm, authorities will need to develop
policies that redress this balance [119]. Finally, while
HTA continues to adapt and evolve in its assessment
and evaluations to personalized medicines, patients may
experience unequal access where public and private drug
coverage differs or in developing economies where prior-
ity may be given to population-based therapies. These is-
sues will need addressing.
There are a number of potential ways forward for all
the six main stakeholder groups to enhance the utilization
and funding for new diagnostic or prognostic tests and
treatment approaches that address the key issues
highlighted above. These can be broken down into general
issues as well as key issues pre-, peri- and post-launch
[116,210].
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Potential issues for key stakeholder groups
The first stakeholder group consists of governments,
health authorities and health insurance agencies
[3,5,27,35,83,97-99,107,109,116,164,191,205,210-227].
The major issues for this group to consider include:
General
 To instigate Pan-European central, online, open-
access repositories of biomarker and potential
genomic tests of personalized therapy including
their clinical utility and therapeutic implications.
The data should be made readily and openly
available to all key stakeholder groups.
 To establish respected groups in each country that
can assess the value of new genetic tests prior to
and during reimbursement or funding discussions.
This builds on current activities in France, the
National Institute for Health and Care Excellence,
UK, the UK Genetic Testing Network and the
Medicines and Healthcare Products Regulatory
Agency in the UK, and the EGAPP working group
in the US. This also builds on developments among
HTA bodies (below).
 To introduce stricter definitions of orphan drug
status to reduce the number of targeted drugs
seeking this definition and their anticipated high
acquisition costs, that is, 5 out of 100,000 rather
than the current 5 out of 10,000 (below).
 To explore collaborative opportunities with
groups such as the European Union Personalised
RNA Interference to Enhance the Delivery of
Individualised Cytotoxic and Targeted
therapeutics consortium, and other European
bodies, to deliver education to providers,
practitioners and patients. This would address
some of the complexities and misunderstanding
that exists among key stakeholder groups
regarding personalized medicine.
 To establish and support networks of professional
medical institutions including Drug and Therapeutic
Committees to promote critical drug evaluation peri-
launch and scientifically founded recommendations.
This also includes groups to assess the sensitivity and
specificity of new diagnostic and prognostic tests and
the implications across populations building on, for
instance, the classification criteria developed by the
EGAPP working group.
 To evaluate new ways of organizing care with
personalized medicine placing particular emphasis
on wellness and disease prevention replacing
hospital-centerd care provision. This includes
increased time between patients and physicians in
primary care to fully explain the findings from any
test to sufficiently empower patients in their
decision making.
 To fully consider the legal consequences of
personalized care including citizens’ autonomy, legal
liability and the protection of any information
generated.
 To refine new models of care broken down by pre-,
per- and post-launch activities that enhance the
utilization of new diagnostic technologies and new
targeted treatments that can improve the care of
patients.
Pre-launch
 To extend current Horizon Scanning, early
assessment and alert systems as well as budget
impact analyses to include new diagnostic and
prognostic biomarkers and genetic tests. The
objective is to ensure that independent information
regarding the clinical utility of new tests, including
issues surrounding their sensitivity and specificity
as well as their overall predictive value, including
data on the extent of false positives and false
negatives, is available when new diagnostic
approaches and new drugs are being considered for
reimbursement. This may mean working initially
with limited evidence while new data is generated.
Such services can build on the activities of
International Networks and EuroScan as well as
Horizon Scanning activities in for instance
Germany, Italy, Sweden and the UK. This should
include an assessment of the likely budget impact
of new diagnostic and prognostic approaches as
well as new targeted treatments, including any
costs avoided. It should also be ascertained
beforehand whether tissue samples can be analyzed
locally, for example, tissue samples have to be sent
from Scotland to the US before initiating treatment
with maraviroc, adding to the cost of treatment.
 As part of this, to initiate early dialogue with
groups such as the European Network for HTA,
country HTA bodies and the European
Medicines Agency, as well as groups developing
mathematical models and system biology
approaches to interpret the findings from
pharmacogenomics studies and their implications
for subsequent patient care.
 Through such dialogue, facilitate discussions on
whether new care pathways and facilities are needed
prior to launch, as well as how new diagnostic and
prognostic tests will be funded, especially if there is
still fragmentation in funding care.
 Where pertinent and feasible, seek partnerships
between health authorities, academic institutions
and commercial organizations to accelerate
developments that can improve care at reduced
costs - especially through greater use of generic
therapies.
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Peri-launch
 If necessary, to adjust the process of HTA and other
assessment bodies to robustly handle the diagnostic
component of new targeted treatments.
 To consider developing new quality indicators
around new targeted therapies together with key
stakeholder groups. This builds on existing
processes. This should include their assessment in
practice acknowledging that any indicators
developed must have validity in terms of content,
face, concurrence, construct and prediction.
 To seek to include new indicators in any new
guidance and guidelines associated with new
targeted treatments, as well as potentially to
consider their inclusion in any ongoing financial
incentive schemes for physicians.
 To be critical of any proposed risk-sharing arrange-
ments including targeted therapies and biomarkers
and to be mindful of the potential administration
costs. However, also aware that such arrangements
post-launch could facilitate reimbursement and
funding of new premium-priced drugs.
 Continually checking likely launch dates for new
treatments with the relevant pharmaceutical
companies to improve financial planning, especially
given the premium prices requested for new
targeted treatments.
Post-launch
 To integrate regular reviews of any reimbursement,
funding or guidance especially as more data
becomes available.
 To monitor physician adherence to any agreed
guidance or reimbursement restrictions for new
targeted treatments.
 To instigate additional demand-side measures such
as educational initiatives and financial incentives if
needed where there are concerns with adherence
rates to any agreed guidance or subpopulations.
The second stakeholder group includes HTA units
[27,33,98,99,228-231]. The major issues for HTA units
include:
General (in addition to providing critical input peri-
launch including the sensitivity and specificity of new
diagnostic and prognostic tests)
 To develop and refine new methodological approaches
that take into account potential changes in clinical
trials and increasing use of models in systems biology-
based personalized medicine approaches - especially
around defining subpopulations.
 Possibly to include progression of constructive
technology assessments until more data become
available. However, to be mindful of concerns with
surrogate data.
 Possibly to involve HTA units with discussions to
modify the legal framework as well as regulatory and
approval processes as more information regarding
personalized medicines become available.
Post-launch
 To assist with post-launch follow-up of drugs
particularly to reassess product safety in routine
clinical care, as well as to provide guidance where
concerns.
The third stakeholder group includes research
institutions, research groups and professional medical,
pharmaceutical and educational societies. The major
issues for this group include:
 To focus and promote comprehensive critical
research and education to understand and explore
the benefits and risks with personalized diagnostic
and treatment strategies.
 To assist with policy analysis and involvement in
education on issues relating to personalized medicine
among specialists, researchers and in the public area.
The fourth stakeholder group are physicians
[3,9,34,49,60,61,107,109,116,184-187,205,212,
217,221,232]. The major issues for physicians include:
General
 To provide independent advice into clinical trial
design for new biomarkers that are disease based;
alternatively aimed at differentiating patients or
populations based on either differences in drug
metabolism, drug transporter capacity or receptor
variants.
 To help design trials that improve our understanding
of the sensitivity and specificity of new diagnostic
tests, thereby reducing the uncertainty with their use.
Such studies could include cohort studies with
samples and data collected prospectively. Nested
case–control studies are also potentially useful so long
as blinding is maintained.
 To assist with the design of technology platforms and
mathematical models that help with future decision
making for individual patients as the complexity of
biological systems unfold. By doing so, to improve the
translation of research results into clinical practice.
 To push for ongoing independent reinterpretation of
the implications of genetic tests and therapies in the
light of new discoveries. This will be achieved
through using trained clinical pharmacologists and
physicians specializing in areas such as molecular
oncology. This builds on the current controversies
surrounding the pre-testing of patients prescribed
clopidogrel or warfarin.
 To help translate the language of genomics into lay
language to assist patients with their decision
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making, including the benefit:risk ratio of
treatments. This will necessarily include improved
knowledge of genomics among physicians from
current low rates.
Pre-launch
 To work with health authorities and health
insurance companies pre-launch to critically
review new targeted treatments, especially where
there are concerns about their potential value in
practice.
 As part of this, to provide guidance to health
authorities and health insurance companies about
potential new quality indicators.
 To provide input into discussions on the potential
value of new pharmacogenetic tests that optimize
the use of new drugs post-launch especially where
there are considerable uncertainties regarding their
clinical value.
Peri- and post-launch
 To assist with the design of any patient registries or
expansion in Electronic Health Records prior to
launch, and follow this up after launch building on
the experiences with, for instance, natalizumab.
 To help authorities critically assess proposed risk
sharing arrangements, especially regarding the
potential administrative burden.
 To assist hospital and ambulatory care Drugs and
Therapeutic Committees with critically evaluating
new targeted treatments, as well as to promote
interface arrangements to improve the co-ordination
of care between primary and secondary care
physicians.
 To help with the development of educational
materials for physicians and patients peri- and post-
launch based on agreed guidance.
The fifth stakeholder group are patients and patient
groups [27,107,109,211,212]. The major issues for this
group include:
General
 To support the development of patient registries and
electronic record systems that help identify patients
with specific genotypes to improve their care in the
future.
 Where pertinent, to work with all key stakeholder
groups regarding potential goals for the sensitivity
and specificity of new molecular and diagnostic
genetic tests alone or in combination to reduce
uncertainty with their use, especially if there is
reluctance to fund ‘coverage with evidence’ schemes.
 To help authorities and physicians involved in the
development of personalized medicine translate the
results of research findings into lay language to
assist patients with future decision making.
 To seek to be an integral part of national discussions
concerning the ethics and implications of genetic
testing for other family members.
 To help authorities incorporate personalized
medicine into patient education schemes to enhance
their understanding of this complex field for better
informed discussions with physicians.
 To work with authorities to make sure that patients’
dignities and integrities are preserved with greater
knowledge of their genetic make-up, and that
specific groups are not excluded from societies
(building on earlier comments).
Pre-launch
 To provide input to health authority and health
insurance companies pre-launch discussions
regarding key issues for new diagnostic tests or new
targeted treatments from a patient’s perspective.
 To support the development of patient registries or
other data collection activities around new targeted
approaches; the results of which can also be used to
inform future clinical trials and future decision
making.
Pre- and peri-launch
 To help with the design and distribution of any
patient information regarding new drugs, especially
where there are potential safety issues.
 To help with the development of new quality
indicators for new targeted drugs from a patient’s
perspective to improve their validity.
 To provide input into the assessment of the
potential value of new technologies especially where
the findings, including potential biomarkers, are
inconclusive.
Post-launch
 To help refine information for patients as more
knowledge becomes available about new diagnostic
approaches or new drugs, especially with respect to
major adverse reactions and their implications.
 To help disseminate factual information to patients,
especially where there are exaggerated claims unduly
raising expectations among patients or where key
issues regarding the potential side-effects of
treatments have not been fully explained or
adequately disseminated.
The last stakeholder group includes pharmaceutical
and diagnostic companies
[11,13,75,88,90,91,98,99,114,116,205,210,211,213,214,
233,234]. The major issues for this group include:
General
 To make explicit in the trial design for new genetic
tests and biomarkers whether they are dealing with
diagnostic or prognostic; alternatively, disease-based
or patient- or population-based technologies.
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This acknowledges that different trial populations will
be needed, as well as different performance
characteristics for different tests. For example, new
screening biomarkers need high specificity to avoid
generating an excessive number of false positives
whereas high sensitivity is needed for new prognostic
biomarkers to avoid denying treatment to patients
who could potentially benefit.
 To make the objectives of any trial design specific to
answer key questions. This includes potential
subpopulations where the health gain of new
targeted drugs is greatest. It also includes designing
studies to specifically answer questions about the
sensitivity and specificity of new diagnostic and
prognostic tests including the extent of any false
positives and false negatives.
Pre-launch
 To instigate realism into corporate discussions
regarding potential requested prices for new
diagnostic tests or targeted treatments,
acknowledging that the cost of providing tests
includes both the acquisition costs as well as facility
costs as resource pressures grow. This becomes even
more important if multiple genetic tests are needed
to plan future care.
 As part of this, to avoid the temptation to seek
‘orphan status’ for new targeted therapies as
resource pressures grow. This may avoid rejection
or delayed funding even with risk-sharing or patient
access schemes to lower acquisition costs. This
includes recognition that without targeting new
products are increasingly unlikely to achieve
premium prices as more standard drugs become
available as generics and niche areas diminish.
 To acknowledge that the definition of orphan drug
status may need redefining to smaller patient
populations, especially with the increasing costs of
orphan drugs and growing resource pressures.
 To seek scientific advice from relevant registration,
HTA and funding bodies pre-launch on the potential
need and relevance for developing markers and tests
concurrently with developing new drugs, especially
for small and medium-sized companies as part of
their development process.
 Similarly, seek scientific advice for new drugs that
require associated genetic testing to maximize their
value especially for clinical trials that could include
small subgroups of patients.
 To explore possible partnerships between
diagnostic and pharmaceutical companies to
provide a combined package at launch, for example,
combined worldwide sales of trastuzumab and
imatinib, both using established tests, were US$9.6
billion in 2010.
 To initiate possible discussions concerning rebates
or discounts peri-launch to enhance the value of
new targeted treatments - recognizing the
complexities of current funding arrangements.
There are a number of issues arising from these consid-
erations that need to be explored further. These include:
 greater cohesion of what is meant by personalized
medicine and associated training
 the Human Microbiome Project
 DTC advertising
 evidence-based classification of genomic tests
 funding of new targeted tests and therapies.
Future direction and training
To enhance acceptance of personalized medicine, there
needs to be greater cohesion of what this constitutes.
The advent of the European Science Foundation recruiting
a group to analyze the complex field of personalized
medicine may help, especially as their objective is to
provide future policy advice [1,36]. This is already
leading to groups such as the European Alliance for
Personalised Medicine issuing five key major action
points for policy makers, politicians and regulators
across Europe to accelerate the development, delivery
and uptake of personalized medicine and diagnostics
[235]. These include:
 ensuring a regulatory and funding environment that
allows early patient access to novel and effective
personalized medicine
 increasing research and development funding to
develop new personalized medicines
 improving the education and training of healthcare
professionals regarding personalized medicine and
the various approaches
 acknowledging that new approaches may be needed
for reimbursement and HTA assessment, which are
required for patient access to personalized medicine
and recognition of their value
 increasing awareness and understanding of
personalized medicine among all stakeholder groups.
The funding of any new diagnostic facilities, as well as
the instigation of patient education, may also be a chal-
lenge as the range of therapeutic options increase and
become more complicated to navigate. Moreover, add-
itional training of healthcare professionals, including
their full understanding of the concepts of personalized
medicine and targeted approaches, will also need to be
addressed [212]. For instance, only 10% of physicians in
the US in a recent survey believed they were adequately
informed about pharmacogenomic testing [212]. However,
Godman et al. BMC Medicine 2013, 11:179 Page 13 of 23
http://www.biomedcentral.com/1741-7015/11/179
we believe that as targeted therapies become more com-
monplace, fluency in genomics will increase and with it
methodologies and training to handle the increasingly
complex biological information. Mathematical models and
decision support tools, together with developments in
technology platforms, will help as well [5,36,123,236,237].
Human Microbiome Project
Following the completion of the Human Genome Pro-
ject, there has been substantial growth in recent years in
the Human Microbiome Project [238,239]. These devel-
opments open up new possibilities and horizons for
studying how microbiome compositional and functional
variations affect the effectiveness of drugs and their tox-
icity (pharmamicrobiomics), most notably in the gut.
This includes research into how the microbiome inter-
acts with human metabolic enzymes in the liver and in-
testine. Ultimately, we must understand better the future
implications of Human Microbiome Project on drug
therapeutics and personalized medicine [238]. Further
discussions are outside the scope of this review paper.
This will be the subject of future research articles.
Direct-to-consumer advertising of genetic testing
One key issue that authorities will need to consider is
the growth in private enterprises offering DTC genetic
testing [47,119]. This builds on the knowledge that per-
sonalized sequencing can deliver some clinically useful
information [47,118,119,240]. While we believe the up-
take of as yet lightly regulated DTC activities by com-
mercial companies may currently only occur in a limited
number of situations, despite such services being access-
ible via mobile devices [119], there are concerns with
their current lack of predictive value, clinical validity and
utility, discordance of results between companies, and
difficulties with interpretation, as well as test-related
anxiety [2,16,47,118,241-245]. Other concerns include
the variable quality of pre-test and post-test information
and genetic counseling services, the lack of medical
supervision among DTC companies, and inappropriate
testing of minors by some [47,118,246,247].
Unregulated, this could be a major source of anxiety
given concerns with the limited clinical utility of some
of the tests to date [47,118,119,242]. This has encour-
aged professional bodies such as the European Society of
Human Genetics and the Nuffield Council of Bioethics
to jointly inform and warn healthcare professionals,
health authorities and the public concerning potential
problematic aspects of DTC genetic testing [118]. How-
ever, it is recognized that it is difficult to have an inter-
national legal framework to control such activities [118].
The European Directive 95/46/EC on the protection of
individuals, and directive 2000/31/EC on certain legal
aspects of information society services in particular
relating to ecommerce, should help address some of
these concerns [118]. Whether this actually works re-
mains to be seen, even if the authorities in France are
already active in regulating individuals against DTC ac-
tivities [118].
Evidence-based classification of genomic tests in clinical
practice
As mentioned, algorithms have been developed in the
US as part of the EGAPP initiative [107,110]. These were
motivated largely by frustration at the lack of evidence
regarding the translation of genomic discoveries into
clinical practice [107,109,110,248].
Key considerations in the recommendations ranging
from ‘do not use in practice’ to ‘implement in practice’
include [107,110]:
 level of evidence
 level of certainty - from low to high
 risk benefit profile - from unknown, unfavorable to
favorable
 extent of additional research needed
 potential health impact
 evidence recommendations and actions.
As mentioned above, only one of the initial four gen-
omic tests was recommended for implementation in
practice using this approach [107].
Funding of new targeted therapies
Additional funding of specific tests for diagnosis,
prognosis and directing treatment options can be a
major concern among health authorities and health
insurance companies (payers) as resource pressures
grow, negating the potential benefits from personaliz-
ing treatment approaches [27]. This is illustrated by
complex tests for patients with breast cancer costing
approximately US$3,900 per test in the US, although
these have been shown to reduce overall treatment
costs [35,92,249]. Overall, the costs for complex tests
range from US$1,000 to over US$4,000 per patient
(2008 US prices) [35].
The UK is seeking to address some of these issues
through establishing the UK Genetic Testing Network
for single-gene disorders [35,250]. However, funding ar-
rangements are still unclear if multiple pharmacogenetic
and microarray-based tests are needed before initiating
treatment [35], although this is changing [251]. This
however may be less of an issue in the future if, as envis-
aged, the costs of these tests appreciably fall in price
with their increasing use [44,201,252]. New funding
mechanisms have also been developed in the UK to
optimize the use of targeted drugs. For instance, the UK
National Health Service agreed to pay AstraZeneca
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directly GB£157.20 to GB£210.00 per Epidermal Growth
Factor Receptor (EGFR) test prior to treatment with
gefitinib as part of the overall strategy for funding the
drug [35]. This is implemented via a network of regional
laboratories.
Funding of pharmacogenomic tests has been helped by
investigators in Japan estimating that KRAS testing in se-
lected patients with colorectal cancer before initiating
cetuximab saved an estimated US$50 million per year
compared to no testing [253,254]. This led to increased
use of cetuximab [23]. KRAS testing has also be esti-
mated to save the US health system over US$600 million
per year in the cost of cetuximab [36,255]. The cost of
treatment for patients with colorectal cancer has also
been reduced in France with the instigation of regional
centers undertaking KRAS resting [47]. Other authors
have also shown that KRAS mutation testing prior to
treatment with cetuximab saved costs [98,256].
However, there are concerns among payers that
targeting of new drugs to small populations will lead to
them being considered as ‘orphan drugs’, potentially
resulting in premium prices above those of new drugs
without orphan status [113-115]. Such cases have already
happened, for example, crizotinib and vemurafenib, which
have been launched at approximately US$10,000 per pa-
tient per month excluding the cost of diagnostic tests and
administration costs [91,257-259]. This is appreciably
higher than for trastuzumab, which, when first launched,
caused considerable funding concerns in some European
countries [260]. This is at a time when the number of new
cancer cases is expected to increase by over 60% in the
next 20 years [49,92,253,260-262]. Other examples of high
acquisition costs include new targeted drugs for patients
with cystic fibrosis, which have been launched at over US
$25,000 per month based on the concept of a targeted
therapy in a selected subgroup of patients with cystic fi-
brosis [88]. More recently in the US, abiraterone was the
only cancer drug approved by the FDA in 2011 without an
orphan designation [112]. This situation can potentially
lead to high acquisition drug costs, appreciably increasing
the overall cost burden [113,233,251]. These concerns
have been fuelled by Sanofi-Aventis in 2011 acquiring
Genzyme for approximately US$20.1 billion [263,264],
which built its base on Ceredase (imiglucerase) for
Gaucher’s disease and subsequently new treatments for
small patient populations with genetic deficiencies. These
costs will need to be recouped. This has resulted in sug-
gestions to reconsider the definition of orphan drugs
discussed earlier.
Conclusions
There should be considerable benefits to all key stake-
holders with new technologies that can improve the
diagnosis, prognosis and treatment of patients, reducing
the number of patients needed to treat and increasing
the number of patients needed to harm. In addition, this
will also reduce the cost and consequences of ADRs
[16,22,26,38,39,74,75] and, as a result, improve the
health of patients within finite resources.
However, the complexity of biological systems means
that gene mutations may not always express themselves
as important phenotypic changes in disease patterns,
making identification of potential biomarkers and new
targeted treatments more difficult. This may explain why
the promise of personalized medicine has not always
translated into improvements in patient care in practice,
and why only a limited number of targeted treatments
are currently available and funded. This may also explain
why advice about certain specific tests has been
retracted as more data becomes available. This includes
CYP2D6 genotyping testing prior to initiation of tamoxi-
fen [5,25,28-31] and CYP2C19 genotyping testing prior
to the initiation of treatment with clopidogrel [180-182].
It is recognized that for new technologies to be
funded, there needs to be improved co-ordination
among groups responsible for the funding of care and
those evaluating new technologies. This will facilitate
funding of new technologies that improve diagnosis,
prognosis or subsequent care, especially if funding for
new personalized technologies cross sectors [26]. This is
beginning to happen as seen in France and the UK
[35,191]. However, this has been the exception, typically
with fragmentation and heterogeneity of funding across
sectors [1,13,35], exacerbated in some cases by the need
for multiple pharmacogenetic and microarray-based tests.
The envisaged reduction in the costs of pharmacogenetic
tests [44,201,252] should increase the number of
pharmacogenetic tests that are currently funded [265].
Earlier planning for the introduction of valued tests
and targeted treatments should also facilitate their
funding. New models, including potential coverage with
evidence schemes [228], should also be explored further
to facilitate funding. However, this will depend on re-
source requirements and the level of evidence initially
provided [107,110,211].
A growing concern among payers is the requested
price for new targeted treatments, especially if these in-
creasingly resemble requested prices for orphan drugs,
which is already happening [88,257-259]. In 2009, 22
targeted cancer therapies were approved by the FDA,
with sales of US$16 billion/year in the US in 2009 alone
for just five of these [11,45,103]. More recently, as men-
tioned, abiraterone was the only cancer drug approved
by the FDA in 2011 that did not seek an orphan designa-
tion [112]. Alongside this, payers are aware of the con-
siderable number of biological drugs in development.
For example, 42% of over 600 drugs in Phase I to III in
companies listed in the NASDAQ Biotech Index are
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biological drugs, the majority of which are for cancer or
immunological diseases [266]. Overall, it is estimated
that up to half of current clinical pipelines among lead-
ing companies include targeted or stratified medicines
[45]. These issues and concerns need to be addressed to
be able to fully fund new premium-priced targeted treat-
ments considered valuable by payers of healthcare.
Payers across Europe are already seeking ways to re-
lease resources to help fund new technologies. This is
through increased use of low-cost generics versus
patented drugs in a class or related class, which will
grow as more standard therapies lose their patents
[83,267-273]. Commercial organizations can play their
part through realistic pricing for their new technologies.
This should be a possibility since developments in
pharmacogenomics should reduce the number of fail-
ures, accelerate drug development and potentially reduce
the number of patients needed in clinical trials through
enriched patient populations [26], resulting in appre-
ciably reduced development costs [50]. Marketing activ-
ities should be lower for targeted treatments with robust
evidence, This should translate into lower prices, with
US$53 billion per year spent in recent years by pharma-
ceutical companies in the US alone on promoting their
products to physicians [274].
Governments and health authorities also need to
tackle the ethical issues associated with an increasing
personalized approach. These include who will own the
genomic data if population-based genomic sequencing
increases, as well as issues of equity if high prices persist
for diagnostic and prognostic tests and for new targeted
treatments [27].
In conclusion, we hope we have stimulated the debate
about personalized medicine and the ways forward for
all key stakeholder groups. As a result, we hope this will
help translate the promise of personalized medicine into
clinical practice to benefit patients in the future.
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